We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia.
- Authors
Fan, Shuangshuang; Wang, Tian; You, Fengtao; Zhang, Tingting; Li, Yafen; Ji, Cheng; Han, Zhichao; Sheng, Binjie; Zhai, Xiaochen; An, Gangli; Meng, Huimin; Yang, Lin
- Abstract
Background and aims: Chimeric antigen receptor (CAR)-T cell therapy is a novel type of immunotherapy. However, the use of CAR-T cells to treat acute myeloid leukaemia (AML) has limitations. B7-H3 is expressed in several malignancies, including some types of AML cells. However, its expression in normal tissues is low. Therefore, B7-H3 is ideal for targeted AML therapy. Materials and methods: First, we constructed B7-H3 CAR that can target B7-H3, and then constructed B7-H3-CAR-T cells in vitro, which were co-incubated with six AML cell lines expressing different levels of B7-H3, respectively. The toxicity and cytokines were detected by flow cytometry. In vivo, AML model was established in B-NSG mice to study the toxicity of B7-H3-CAR T on AML cells. Results: In vitro functional tests showed that B7-H3-CAR-T cells were cytotoxic to B7-H3-positive AML tumor cells and had good scavenging effect on B7-H3-expressing AML cell lines, and the cytokine results were consistent. In vivo, B7-H3-CAR-T cells significantly inhibited tumor cell growth in a mouse model of AML, prolonging mouse survival compared with controls. Conclusion: B7-H3-CAR-T cells may serve as a novel therapeutic method for the targeted treatment of AML.
- Publication
European Journal of Medical Research, 2023, Vol 28, Issue 1, p1
- ISSN
0949-2321
- Publication type
Article
- DOI
10.1186/s40001-023-01049-y